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The poor prognosis of Glioblastoma Multiforme (GBM) is due to a high resistance to conventional
treatments and to the presence of a subpopulation of glioma stem cells (GSCs). Combination therapies
targeting survival/self-renewal signals of GBM and GSCs are emerging as useful tools to improve GBM
treatment. In this context, the hyperactivated AKT/mammalian target of the rapamycin (AKT/mTOR) and
the inhibited wild-type p53 appear to be good candidates. Herein, the interaction between these pathways
was investigated, using the novel AKT/mTOR inhibitor FC85 and ISA27, which re-activates p53
functionality by blocking its endogenous inhibitor murine double minute 2 homologue (MDM2). In GBM
cells, FC85 efficiently inhibited AKT/mTOR signalling and reactivated p53 functionality, triggering cellular
apoptosis. The combined therapy with ISA27 produced a synergic effect on the inhibition of cell viability
and on the reactivation of p53 pathway. Most importantly, FC85 and ISA27 blocked proliferation and
promoted the differentiation of GSCs. The simultaneous use of these compounds significantly enhanced
GSC differentiation/apoptosis. These findings suggest that FC85 actively enhances the downstream p53
signalling and that a combination strategy aimed at inhibiting the AKT/mTOR pathway and re-activating
p53 signalling is potentially effective in GBM and in GSCs.
G lioblastomas (GBMs) are one of the most aggressive and deadly forms of human cancer. GBM treatmentusually consists of surgical resection followed by radiotherapy combined with the alkylating agenttemozolomide (TMZ)1. Although this therapeutic approach slightly improves the survival rate of
GBM patients, a large fraction of these patients suffer from tumour recurrence1.
Accumulating evidence suggests that tumour relapse may be driven by a component of heterogeneous tumour
cells that retain stem cell-like properties, called ‘‘cancer stem cells’’ (CSCs). The potent tumourigenic capacity of
glioma CSCs (GSCs), coupled with evidence of radio- and chemo-resistance, suggests that a stem cell-orientated
therapy may represent an innovative strategy to reduce tumour recurrence and improve GBM prognosis2.
Two main strategies are currently exploited to eradicate the heterogeneous population of GBM and GSCs:
(a) chemotherapeutic regimens that specifically drive GSCs into cell death, and (b) driving GSCs into differenti-
ation, thereby depleting the tumour reservoir. The latter strategy appears the most promising, considering that
differentiated cells are in general more sensitive to chemotherapeutic agents with respect to CSCs3.
Studies on human GBM samples have uncovered that the deregulation of signal transduction pathways is one
of the most prominent4,5. The disruption of signal transduction in GBM occurs through over-expression or a
gain-of-function mutation of tyrosine-kinase receptors6,7, thus leading, among other events, to constitutive
activation of Ras/extracellular signal-regulated kinase (ERK), AKT/mammalian target of rapamycin (mTOR).
As a result, AKT is elevated in the majority of examined GBMs8,9 with the subsequent amplification of pro-
survival signals and blockage of oncosuppressor controls. The inactivation of the oncosuppressor protein p53 is
certainly one of the main phenomena that allow GBM cells to escape cell cycle checkpoints. In particular, the
intracellular levels of p53 are maintained low due to an excessive stimulation (mediated by AKT constitutive
activation10) of the ubiquitin-ligase murine double minute 2 homologue (MDM2), the predominant natural
endogenous inhibitor of the protein p5311,12. In addition to accelerating p53 degradation, MDM2 prevents p53
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binding to DNA, blocking its transcriptional activity. As GBM cells
typically express p53 with a wild-type amino acid sequence, the
re-activation of p53 functionality can be restored through the inhibi-
tion of the oncogenic block exerted by the AKT/mTOR pathway,
which causes an excessive stimulation of MDM2. In this respect,
while agents inhibiting either the AKT/mTOR pathway13–15 or the
MDM2/p53 interaction16–18 have provided some survival benefit in
GBM, the effects of a co-therapy have not been deeply investigated to
date, either in GBMs or in their stem cells. In acute myeloid leuk-
aemia, the PI3K/mTOR inhibitor PI-103 acts synergistically with
the MDM2 inhibitor nutlin-3 to induce apoptosis in a wild-type
p53-dependent fashion19, supporting the aforementioned mech-
anistic rationale.
In our previous work, a series of 2-oxindole derivatives (OXIDs)
have been described20 and demonstrated to act as inhibitors of the
AKT/mTOR pathway. Herein, we identified FC85 as a new ligand,
useful in establishing the preclinical proof of concept for the
AKT/mTOR pathway, and whose activity could be amplified by
co-treatment with an MDM2 inhibitor. The mechanism of action
of FC85 was examined alone or in combination with an already
characterized inhibitor of MDM2, ISA2718, both in GBM cells and
in their derived GSCs. In parallel experiments, the oral mTOR inhib-
itor everolimus21,22 and the MDM2 inhibitor nutlin-317,18 were also
used as reference compounds. Globally, our findings demonstrated
that AKT/mTOR inhibitors actively enhance downstream p53
signalling and that a combination strategy aimed at inhibiting
the PI3K/AKT/mTOR pathway and activating p53 signalling is
potentially effective in GBMs and in GSCs (Fig. 1a).
Results
Design and Synthesis. Over recent years, new compounds with an
indole/oxindole core have been widely investigated as agents able
to target the activity of the serine/threonine kinases PDK1 and/or
AKT23. Recently, we synthesized new OXIDs compounds by
the combination of a tetrahydroisoquinoline nucleus with the
2-oxindole nucleus throughout a methylenamido moiety, and
anchoring the 3-position of oxindole core to different heterocycles
(Fig. 1b and c). The new OXIDs24 induced cell cycle arrest and
inhibited AKT phosphorylation in non-small cell lung cancer cells
(which overexpress the PI3K/AKT/mTOR pathway and show
resistance to EGFR inhibitors), suggesting that the OXID nucleus
can be used as central core to develop inhibitors of the PI3K/AKT/
mTOR pathway. Specifically, we afforded the replacement of the
amido moiety of OXIDs (Fig. 1b and c) with its bioisosteric
amidosulfonyl group. Sulfonamide is a well-known pharmacofore
notorious as key element to confer anticancer properties, among
others25,26.
FC85 was obtained as depicted in Figure 1b. Briefly, the 5-amino-2-
oxindole 1 reacted with p-toluenesulfonyl chloride to give 4-methyl-N-
(2-oxoindolin-5-yl)benzenesulfonamide2. The subsequentKnoevenagel
condensation of 2with the 1H-imidazole-5-carboxaldehyde afforded the
target compound as a Z-isomer. In co-treatment experiments, we used
the small-molecule MDM2 inhibitor with a spirooxoindolepyrrolidine
core structure, ISA27, which was synthesized as previously described27.
Effects of FC85 on the AKT/mTOR signalling pathway in U87MG
cells.As a representative GBM cell line, we used U87MG cells, which
is an appropriate model to study the interaction between the AKT/
mTOR and MDM2-p53 pathways because of the following
characteristics: i) U87MG cells maintain a wild type status of p53,
and ii) U87MG cells are deficient for the tumour suppressor
phosphatase and tensin homologue (PTEN), a negative regulator
of the PI3K/AKT pathway; moreover, PTEN deficiency leads to
MDM2 nuclear accumulation, thus inhibiting p53 functions28.
To assess whether FC85 could effectively inhibit the mTOR/AKT
pathway in U87MG cells, the effects of the new compound on AKT
and mTOR activity were examined. FC85, tested at 100 nM, 1 mM
and 10 mM, significantly inhibited AKT phosphorylation at Ser473
(Suppl. Fig. 1a), as reported for the already published OXIDs24. The
new compound reduced also mTOR constitutive phosphorylation at
Ser2448 (Suppl. Fig. 1b). These findings demonstrated that FC85 was
able to target the AKT/mTOR signalling pathway in U87MG cells.
Effects of FC85 on U87MG cell viability. To examine the effects of
FC85 on GBM cell growth/survival, U87MG cells were incubated
with different concentrations of the compound for 24 h this new
compound showed a dose-dependent inhibitory effect on the growth/
survival ofU87MGcells, with an IC50 value of 468.9648.9 nM (Fig. 2a).
Trypan blue exclusion experiments confirmed a concentration-
dependent decrease of live cells and an increase of dead cells (Fig. 2b).
To assess whether U87MG cells could resume proliferation, cells were
treated for 96 h with the compound at 10 mM. At the end of the
treatment period, the culture medium was replaced with fresh
medium not containing the drug. As depicted in Figure 2c, the
number of viable cells did not significantly increase at either 1 or 3
days of wash-out with respect to control samples, suggesting the
inability of cells to recover normal growth.
To determine compound toxicity in non-tumour cells, we exam-
ined the effects of FC85 on the viability of normal Human Umbilical
Vein Endothelial Cells (HUVECs). As shown in Figure 2d, the viab-
ility of HUVECs was significantly decreased after a 48 h incubation
with FC85 used at 1 mM and 10 mM. However, the effects on cell
viability were not strictly concentration dependent, and the percen-
tages of cell viability reduction were significantly lower with respect
to those observed in U87MG cells, suggesting that the anti-prolif-
erative effect elicited by FC85 was directed preferentially towards
tumour cells.
Effect of a combined therapy with an inhibitor of MDM2/p53
complex on U87MG cell viability. Because the inhibition of PI3K/
AKT/mTOR signalling can augment p53-mediated apoptosis29,
AKT/mTOR may synergize with inhibitors of the MDM2/p53
complex to promote anti-tumoural activity in GBM cells that
retain p53 function. To this end, we investigated the effects on
U87MG cell viability of combining doses of FC85 with the already
characterized MDM2 inhibitor, ISA2718. The theoretical additive
IC50,add values for the two drugs were calculated for two fixed
ratios (1:2, 1:5), and the experimental IC50,mix values were
determined for the same fixed-ratio combinations in the viability
assay (Fig. 3a). Statistical analysis of the data from isobolographic
analysis revealed synergistic interactions between FC85 and ISA27
for the two examined fixed-ratio combinations (Suppl. Table S1;
Fig. 3a). Similar experiments were performed using the oral mTOR
inhibitor everolimus, currently in clinical use for several type of solid
tumours21,22, including GBMs (NCT00823459, NCT00831324,
NCT00613132, NCT00553150, NCT00387400, NCT00085566,
NCT00805961) and the MDM2 inhibitor nutlin-3, whose oral
formulation has completed the first early phase clinical trials
for both solid cancers and haematological malignancies30,31.
Everolimus and nutlin-3 alone inhibited U87MG cell proliferation,
yielding an IC50 of 50.062.8 nM and 10.361.1 mM, respectively
(Suppl. Fig. 2a). When combined, the two reference agents showed
a synergic reduction of U87MG cell viability for both the examined
fixed-ratio combinations (Suppl. Table S2; Suppl. Fig. 2b). Globally,
these results confirmed that a combined therapy with an inhibitor of
MDM2/p53 complex and an inhibitor of the AKT/mTOR pathway
could be a useful anti-proliferative strategy in GBM cells.
We then examined the effects of cell treatment with FC85, alone or
in combination with ISA27, on the reactivation of p53 pathway,
assessing accumulation of p53 protein and transcription induction
of p53 target genes. The incubation of GBM cells with FC85 alone
for 6 h led to a slight but significant increase in p53 protein levels
(Fig. 3b and c). As expected, challenging cells with ISA27 caused a
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Figure 1 | (a) Diagram of AKT/mTOR andMDM2/p53 signalling crosstalk in GBM and in GSCs. AKT/mTOR deactivation decreases MDM2 and p53
phosphorylation and increases stable p53, which triggers its downstream targets. Simultaneously, p53 may increase PTEN to suppress AKT activation
further. FC85 inhibited both AKT (Ser473) and mTOR (Ser2448) phosphorylation. ISA27 dissociated the MDM2-p53 complex, thus re-activating p53.
The combined therapy with FC851ISA27 more efficiently re-activated the p53 pathway, producing a synergic effect on the inhibition of GBM cell
viability; most importantly, the simultaneous inhibition of AKT/mTOR and of the MDM2-p53 complex led to a synergic effect in triggering cellular
differentiation/apoptosis of GSC subpopulation. (b) The design of FC85 starting from the general structure of OXIDs. (c) The synthetic procedure for the
preparation of FC85.
www.nature.com/scientificreports
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Figure 2 | Effect of FC85 on U87MG and HUVEC cell viability. (a) U87MG cells were treated in complete medium with the indicated FC85
concentrations for 24 h. At the end of treatment, cell viability was measured using the MTS assay. The data are expressed as a percentage with respect to
that of untreated cells (control), which was set to 100%, and are the mean values 6 SEM of three independent experiments, each performed in duplicate.
(b) U87MG cells were treated as in (a); live and dead cells were then estimated using the trypan blue exclusion test. The data are expressed as the cell
number per well and are the mean values 6 SEM of two independent experiments, each performed in triplicate. The significance of the differences was
determined with a one-way ANOVA with Bonferroni post-test: *** p,0.001 vs. control live cells; ##p,0.01, ### p,0.001 vs. control dead cells.
(c) U87MG cells were treated with 10 mMFC85 for 24 h or 96 h, and then, themediumwas replaced with drug-free freshmedium for another 24 h or 72 h.
At the end of the treatment period, cell viability wasmeasured using theMTS assay. The data are expressed as a percentage with respect to that of untreated
cells (control), which was set to 100%, and are the mean values 6 SEM of three independent experiments, each performed in duplicate. The significance
of the differences was determined with a one-way ANOVA with Bonferroni post-test: *** p,0.001 vs. control. (d) U87MG (black bars) or HUVEC
(white bars) cells were treated with different FC85 concentrations for 48 h. Cell viability was measured using the MTS assay. The data are expressed as a
percentage with respect to that of untreated cells (control), which was set to 100%, and are the mean values 6 SEM of three independent experiments,
each performed in duplicate. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test: * p,0.05,
*** p,0.001 vs. respective control; #p,0.05, ##p,0.01 vs. U87MG cells.
www.nature.com/scientificreports
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Figure 3 | Synergistic effect of FC85 and ISA27 on the survival/growth of U87MG cells and on the reactivation of p53 pathway. (a) Isobologram 2-D
showing the interactions between FC85 and ISA27 in MTS viability tests performed in U87MG cells treated for 24 h with FC85 and/or ISA27.
The IC50 values for FC85 and ISA27 are shown on the X- and Y-axis, respectively. The open points (#) on the additivity line depict the theoretical
IC50,add values for total dose expressed as the proportion of FC85 and ISA27 that produced a 50% effect. The solid points ($) depict the experimental
IC50,mix values for total dose expressed as the proportion of FC85 and ISA27 that produced a 50% effect. (b) U87MG cells were treated for 6 h with DMSO
(control), 500 nM FC85 or 2.5 mM ISA27, alone or in combination. Lysates were subjected to western blot analysis using an antibody to p53. One
representative Western blot is presented (b) for each cell treatment. b-actin was used as the loading control. The bar graph (c) shows the quantitative
analysis of theWestern blots, performed using ImageJ. The data are expressed as the percentage of optical density of the immunoreactive band relative to
that of the control, set to 100%, and are the mean values 6 SEM of three different experiments. The significance of the differences was determined with a
one-way ANOVA with Bonferroni post-test: *p0.05, ***p,0.001 vs. control; ## p,0.01 vs. FC85 alone; 11 p,0.01 vs. ISA27 alone. Full-length blots are
presented in the Supplementary Information section titled ‘‘Full-length blots relative to the cropped images showed in the main Figures’’. (d) U87MG
cells were treated as in b. The relativemRNAquantification of p53 target genes (PUMA, p21 andMDM2)was performed by real-time RT-PCR as describe
in the Methods section. The data are the mean values 6 SEM of three different experiments, each performed in duplicate. The significance of the
differences was determined with a one-way ANOVA with Bonferroni post-test: *** p,0.001 vs. control; ## p,0.01, ### p,0.001 vs. FC85 alone;
11 p,0.01, 111 p,0.001 vs. ISA27 alone.
www.nature.com/scientificreports
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higher accumulation of p53. When cells were treated with FC85 and
ISA27, a significant enhancement of p53 protein accumulation with
respect to cells treated with FC85 or ISA27 alone was observed
(Fig. 3b and c). In line with these data, short-term (6 h) treatment
of U87MG cells with FC85 or ISA27 led to a significant increase in
themRNA levels of certain p53 target genes (Fig. 3d): p21, a cell cycle
inhibitor; PUMA, a gene product required for p53-controlled
intrinsic apoptosis pathway; and MDM2, physiological inhibitor of
p53, and its main transcriptional target. These results suggested that
p53 stabilization in FC85-treated GBM cells led to an increase in
MDM2, PUMA and p21 mRNA levels in a manner that was consist-
ent with the activation of the p53 pathway. Moreover, a significant
enhancement of the transcription of p53 target genes was observed in
FC85-ISA27 co-treated cells with respect to single agent-treated cells
(Fig. 3d).
In parallel experiments, neither nutlin-3 (10 mM) nor everolimus
(50 nM) alone induced a significant accumulation of p53 protein in
short-term (6 h) treatment (Suppl. Fig. 3a and b). These data are
consistent with those previously reported for nutlin-318. When com-
bined, the reference agents produced a significant p53 accumulation
after 6 h of treatment (Suppl. Fig. 3a and b).
Real time RT-PCR experiments showed that nutlin-3 did not
induce any significant increase in p53 target gene products after 6
h of treatment (Suppl. Fig. 3c), according to published data18. Similar
results were obtained with everolimus (Suppl. Fig. 3c).When the two
drugs were used together, a significant increase in MDM2 mRNA
was noticed (Suppl. Fig. 3c). These data are consistent with those
obtained in western blotting analysis and suggest that the combined
therapy could reactivate p53 function with increased efficacy com-
pared with single therapy.
To examine whether the p53 function was effectively reactivated
after a prolonged exposure time, U87MG cells were incubated with
everolimus and/or nutlin-3 for 24 h. Both agents caused a significant
induction of MDM2 and p21 mRNA levels (Suppl. Fig. 3d).
Moreover, a synergistic and significant induction of PUMA mRNA
level was noticed when the two drugs were combined (Suppl. Fig. 3d).
Globally, these results demonstrate that nutlin-3 and everolimus
caused a slower re-activation kinetics of p53 function with respect
to FC85 and ISA27.
Effect of FC85, ISA27 and of their combined treatment on the
induction of apoptosis and cell cycle block. Challenging U87MG
cells with FC85 (500 nM) induced a significant phosphatidylserine
externalization, both in the absence (early apoptosis) or presence of
7-amino-actinomysin binding to DNA (late apoptosis/death; Fig. 4a
and b). These data are consistent with the observed increase of
PUMA mRNA level (Fig. 3d). Similar results were observed with
the MDM2 inhibitor ISA27 (Fig. 4a and b). When the two drugs
were combined together, a significant enhancement in the
percentage of cells in late apoptosis/death was detected, with
respect to cells treated with ISA27 or FC85 alone (Fig. 4a and b).
These findings suggest that the combined therapy may accelerate
apoptosis induction in U87MG cells.
In contrast, everolimus or nutlin-3 did not induced a significant
level of apoptosis in U87MG cells within 24 h of treatment (Suppl.
Fig. 4), consistent with previously published data17,18,32,33. However,
the co-treatment induced a slight but significant induction of
apoptosis (Suppl. Fig. 4), suggesting that everolimus could accelerate
the induction of apoptosis elicited by nutlin-3 in more prolonged
treatment17,18. These data are consistent with those observed in real-
time RT-PCR experiments: after 24 h of incubation, the levels of
PUMAmRNA, a p53-target gene productmainly involved in cellular
apoptosis, were indeed significantly higher only when nutlin-3 and
everolimus were used in combination.
Cell cycle analysis demonstrated that challenging U87MG
cells with FC85, as well as with ISA27, for 24 h arrested cell-cycle
progression in the G0/G1-phase (Fig. 4c and d). U87MG incubation
with both FC85 and ISA27 was able to induce a significantly higher
blockage in the G0-G1 phase compared with single-compound
treated cells (Fig. 4c and d). These results suggest that cell cycle arrest
may have been a contributing factor in the observed increased sens-
itivity of GBM cells to the combined therapy.
Effects of FC85, ISA27 and of their combined treatment on GSC
viability. A hyper activation of the AKT/mTOR pathway has been
reported to play a pivotal role in GBM proliferation as well as in the
self-renewal and propagation of GSCs. On this basis, we evaluated
the effects of FC85 onGSCs, isolated fromU87MG cells as previously
reported34. As depicted in Figure 5a, when GSCs were incubated with
this new compound (1 mMor 10 mM), a significant inhibition of cell
proliferation occurred starting from four days of treatment. Similar
results were obtained using ISA27 (Fig. 5b). A dose-response curve of
FC85 and ISA27 was then performed after seven days of treatment:
the two compounds were able to induce a concentration-dependent
inhibition of GSC proliferation, with IC50 values of 104612 nM and
540668 nM, respectively (Fig. 5c).
In parallel experiments, nutlin-3 reduced GSC proliferation start-
ing from four days of incubation, yielding an IC50 value of
18.562.1 mM after seven days of incubation (Suppl. Fig. 5b and c).
Everolimus exhibited a high ability in reducing GCS proliferation
starting from 24 h of cell treatment and showing an IC50 value of
15.061.2 nM (Suppl. Fig. 5a and c).
The effects of a combined administration of FC85 and ISA27 were
then investigated inGSCs. Isobolographic analysis revealed amarked
synergic effect on the reduction of GSC proliferation, when the two
compounds were used together (Suppl. Table S3; Fig. 5d), suggesting
that a combined therapy with an inhibitor of the MDM2/p53 com-
plex and an inhibitor of the AKT/mTOR pathway can be useful
in GSC-orientated therapy. Similar synergistic interactions were
confirmed also using everolimus and nutlin-3 (Suppl. Fig. 5d;
Suppl. Table S4).
Next, we assessed whether FC85 and/or ISA27-treated cells could
resume proliferation after drug removal. After GSC challenging with
FC85 or ISA27, and a wash-out period of seven and fourteen days,
the percentages of proliferating/viable cells did not significantly
increase, suggesting an overall inability to recover normal growth
(Fig. 5e). These effects were particularly evident when the two
compounds were used simultaneously (Fig. 5e).
Effects of FC85, ISA27 and of their combined treatment on the
induction of GSC apoptosis. We then investigated whether the
reduction of GSC proliferation elicited by the two compounds was
associated with apoptosis. After seven days of GSC treatment, both
FC85 and ISA27 induced a significant phosphatidylserine externa-
lization, both in the absence (early apoptosis) or in the presence of 7-
amino-actinomysin 11 binding to DNA (late apoptosis/death; Fig. 6a
and b). The simultaneous incubation of GSCs with the two
compounds induced both early and late apoptosis; the percentage
of late apoptosis-death was significantly higher with respect to those
observed with the two compounds alone (Fig. 6a and b). Of note,
whereas nutlin-3 alone did not show any significant effects on GSC
apoptosis, everolimus induced slight but significant early apoptosis
after seven days of treatment (Suppl. Fig. 6).When used together, the
two reference drugs caused a strong induction of early apoptosis,
with significantly higher effects with respect to those obtained in
single agent-treated GSCs (Suppl. Fig. 6). These results confirmed
that the chosen combined therapy could accelerate the induction of
GSC apoptosis.
Effects of FC85, ISA27 and of their combined treatment on GSC
morphology and differentiation. The effects of FC85 and ISA27 on
GSCmorphology were evaluated by quantifying the area occupied by
the cells in culture plates as well as the outgrowth of cellular
www.nature.com/scientificreports
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Figure 4 | The effect of FC85 and/or ISA27 on U87MG cell apoptosis and cell cycle. (a, b) U87MG cells were treated for 24 h with DMSO (control), or
500 nM FC85 or 2.5 mM ISA27, alone or in combination. At the end of the treatment period, the cells were collected, and the level of phosphatidylserine
externalisation was evaluated using the Annexin V-staining protocol, as described in the Methods section. b) The data are expressed as the percentage of
apoptotic cells (the data for the early-stage apoptotic cells shown inwhite, and the data for the late-stage apoptotic/necrotic cells shown in grey) versus the
total number of cells. The data shown represent themean6 SEMof three different experiments. The significance of the differences was determined with a
one-way ANOVAwith Bonferroni post-test: *** p,0.001 vs. control; ### p,0.001 vs. FC85 alone; 111 p,0.001 vs. ISA27 alone. (c, d) U87MG cells were
treated as in a. At the end of the treatment periods, the cell cycle was analysed as described in theMethods section. Representative cell cycle histograms of
untreated and treated cells are shown (c). The data are expressed as the percentage of cells in the different phases (G0/G1, G2 or S) versus the total
cell number and are the mean values 6 SEM of three different experiments. The significance of the differences was determined with a one-way
ANOVA with Bonferroni post-test: * p,0.05, ** p,0.01 vs. control in the respective cellular phase; # p,0.05, ## p,0.01 vs. FC85 alone; 1 p,0.05,
11 p,0.01 vs. ISA27 alone.
www.nature.com/scientificreports
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Figure 5 | Effect of FC85 and/or ISA27 onGSC proliferation/viability.U87MG-derived GSCs were incubated with the indicated concentrations of FC85
(a) or ISA27 (b) for 24 h, four days or seven days. At the end of the treatment periods, cell viability wasmeasured using theMTS assay. (c) U87MG-derived
GSCs were incubated for 7 days with increasing concentrations of FC85 or ISA27, and cell viability was measured using the MTS assay. The data are
expressed as a percentage with respect to that of untreated cells (control), which was set to 100%, and are the mean values 6 SEM of three independent
experiments, each performed in duplicate. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test:
* p,0.05, ** p,0.01, *** p,0.001 vs. control. (d) Isobologram 2-D showing the interactions between FC85 and ISA27 inMTS viability tests performed
inU87MG-derived CSCs treated for seven days with FC85 and/or ISA27. The IC50 values for FC85 and ISA27 are shown on the X- andY-axis, respectively.
The open points (#) on the additivity line depict the theoretical IC50,add values for total dose expressed as the proportion of FC85 and ISA27 that
produced a 50% effect. The solid points ($) depict the experimental IC50,mix values for total dose expressed as the proportion of FC85 and ISA27 that
produced a 50% effect. (e) U87MG-derived GSCs were incubated with FC85 and/or ISA27 for seven days; then, the medium was replaced with drug-free
freshmedium for other seven or fourteen days. At the end of the treatment period, cell viability wasmeasured using theMTS assay. The data are expressed
as a percentage with respect to that of untreated cells (control), which was set to 100%, and are themean values6 SEMof three independent experiments,
each performed in duplicate. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test: **p,0.01,
*** p,0.001 vs. control.
www.nature.com/scientificreports
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Figure 6 | The effect of FC85 and/or ISA27 on GSC apoptosis/differentiation. (a, b) GSCs were treated for 7 days with NSCmedium containing DMSO
(control), or 500 nM FC85 or 2.5 mM ISA27, alone or in combination. At the end of treatments, the cells were collected and the degree of
phosphatidylserine externalisation was evaluated using the Annexin V protocol, as described in the Method section. b) The data were expressed as the
percentage of apoptotic cells (early-apoptotic in white, late-apoptotic/necrotic in grey) relative to the total number of cells. The data are the mean
values 6 SEM of three different experiments. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test:
*** p,0.001 vs. control; ### p,0.001 vs. FC85 alone; 111 p,0.001 vs. ISA27 alone. (c) GSCs were treated as in a; total RNA was extracted, and the
relative mRNA quantification of the stem cell markers CD133 and nestin, the neuronal marker MAP, the astrocyte marker GFAP, and of the
oligodendrocyte marker Olig2 was performed by RT-PCR. The data are expressed as the fold change vs. the levels of the control and are the mean
values 6 SEM of three different experiments. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test:
* p,0.05, ** p ,0.01, *** p,0.001 vs. control; ### p,0.001 vs. FC85 alone; 11 p,0.01, 111 p,0.001 vs. ISA27 alone.
www.nature.com/scientificreports
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processes. When GSCs were incubated with FC85 for seven days, an
almost complete reduction in the area occupied by the floating
spheres was noticed, and the cells showed prominent outgrowth of
processes (Fig. 7a-c), as previously reported as a response to other
AKT/mTOR inhibitors35,36. Similar results were obtained with the
MDM2/p53 inhibitor (Fig. 7a-c), suggesting that the reactivation
of the p53 pathway could also induce GSC differentiation. In both
cases, the morphology of differentiated cells appeared to be
heterogeneous, suggesting that FC85 and ISA27 could promote cell
differentiation towards more than one phenotype. When FC85 and
ISA27 were combined, a marked reduction in the size of neuro-
spheres was evidenced, with few cells presenting small cellular
processes (Fig. 7a-c).
To investigate the mechanisms through which FC85 and ISA27
affect GSC morphology, we then assessed the levels of stem and
differentiation markers upon stimulation with the two compounds.
In FC85-treated GSCs, a significant decrease in the stemness mar-
kers, CD133 and Nestin, was noticed (Fig. 6c) accompanied by a
significant increase of MAP and GFAP content, demonstrating that
FC85 was able to promote GSC differentiation towards a neuronal
and a glial phenotype. Similar results were obtained with ISA27
(Fig. 6c). Surprisingly, despite the fact that no significant cellular
processes had been noticed in the morphological analysis, when cells
were treated with the two drugs, a significant decrease in the stem-
ness markers was evidenced, together with a marked increase in the
MAP, GFAP and Olig2 content (Fig. 6c). Moreover, the enhance-
ment of the neuronal and of the astrocyte markers were significantly
higher in FC851ISA27-treated cells with respect to that observed in
single agent-treated cells (Fig. 6c). Comparing the morphological/
apoptosis analysis and RT-PCR data indicated that combined ISA27
and FC85 not only induced the apoptosis of GSCs but also promoted
the differentiation of these cells.
Effects of FC85, ISA27 and of their combined treatment on the
kinetics of AKT and ERK1/2 phosphorylation. The putative
intracellular signalling pathways underlying the effects elicited by
the MDM2/p53 and the AKT/mTOR inhibitors were then investi-
gated. Different signalling pathways have been demonstrated to play
a pivotal role inGSC proliferation and differentiation37; among these,
several evidence suggested that a crosstalk between the PI3K/AKT/
mTOR and MEK/ERK pathways in the maintenance of self-renewal
and tumourigenicity of GSCs38. To study in depth the mechanism
underlying the observed effects, the kinetics of AKT and ERK1/2
inhibition were investigated. GSC incubation with FC85 and/or
ISA27 did not alter total ERK or AKT levels (Suppl. Fig. 7). Both
FC85 and ISA27 induced a fast and significant inhibition of AKT
phosphorylation, which persisted up to 60min (Fig. 8a). Challenging
cells with both compounds prolonged p-AKT inhibition up to 120
min, with significantly higher percentages of inhibition with respect
to single agent-treated cells (Fig. 8a).
Both ligands also affected p-ERK1/2, although showing a transient
blockage (up to 30 min of GSC incubation, Fig. 8b). In contrast,
FC851ISA27 produced a significant and sustained inhibition of
ERK1/2 activity (up to 120 min); as in the case of p-AKT, the per-
centages of inhibition were significantly higher with respect to single
agent-treated cells at 60 and 120 min of GSC treatment (Fig. 8b).
These results are in line with the additive/synergic effect on GSC
differentiation elicited by the co-treatment FC851ISA27, and sup-
port the previous demonstration that the dual and sustained inhibi-
tion of PI3K/AKT/mTOR and MEK/ERK signalling induced
differentiation and inhibited the tumourigenicity of GSCs38.
Discussion
In this study, we report the interactions of PI3K/AKT/mTOR and
MDM2/p53 pathways in GBM cells, following the simultaneous
inhibition of AKT/mTOR signalling and re-activation of the p53
pathway. First, we showed that a combined therapy utilizing the
novel mTOR/AKT inhibitor FC85 and the MDM2/p53 inhibitor
ISA27 produced a synergistic effect on the inhibition of GBM cell
viability as well as on the reactivation of p53 pathway. Most impor-
tantly, similar synergistic effects were shown in GBM-derived CSCs,
where the simultaneous use of the two compounds induced a strong
differentiation of GSCs, as well as apoptosis. A synergistic inhibition
of cell viability of both GBM and its derived CSCs was evidenced also
using the mTOR inhibitor everolimus and the MDM2 inhibitor
nutlin-3 as reference compounds. These findings suggest that a
combination strategy aimed at inhibiting AKT/mTOR signalling
and re-activating p53 signalling may be potentially effective in
GBMs and GSCs.
The multi-targeted strategy has assumed great importance in
GBM therapy, based on the evidence that single-agent therapy is
often not sufficient to control this tumour39–41. Because the hyper-
activation of the PI3K/AKT/mTOR pathway and the inactivation of
wild-type p53 by MDM2 over-expression are frequent molecular
events in highly proliferative tumours, and the aforementioned path-
ways are directly related29, a combined therapy with an inhibitor of
AKT/mTOR pathway and a compound able to inhibit the MDM2/
p53 interaction may represent a valuable approach in GBM. In this
respect, a cell-based screen has demonstrated the efficacy of such
combined therapy in several cancer cells42, thus providing a frame-
work for the rational design of new clinical trials.
We found that FC85 inhibited mTOR and AKT constitutive activ-
ity in U87MG cells; as a result, the new compound decreased cell
viability, induced cell cycle block, and triggered apoptosis. Moreover,
the inhibition of cell viability was long-lasting and directed preferen-
tially towards tumour cells, as demonstrated by the significantly
lower effects observed in HUVECs. Real time RT-PCR and western
blotting analyses demonstrated that FC85 alone led to the accumula-
tion of p53 protein levels and to an increase of the mRNA levels of
p53-target genes, demonstrating a reactivation of the p53 pathway.
Challenging cells with FC85 and the MDM2/p53 inhibitor ISA27
caused an amplification response on the reactivation of the p53
signalling pathway. As a result, such combined therapy produced
synergistic effects on the inhibition of cell viability and enhanced
the induction of p53-mediated apoptosis and cell cycle block with
respect to those elicited by the use of a single agent.
A synergistic inhibition of GBM cell viability was confirmed using
the mTOR inhibitor everolimus and the MDM2 inhibitor nutlin-3.
However, slight differences were noted. When used alone, everoli-
mus and nutlin-3 caused slower reactivation kinetics of p53 function
comparedwith FC85 and ISA27, displaying a significant induction of
p53 target genes only after 24 h of cell treatment, accordingly to data
previously reported for the MDM2 inhibitor18. Moreover, neither
everolimus nor nutlin-3 alone induced apoptosis of U87MG cells
within 24 h of treatment, in line with literature findings, reporting
a non-apoptotic mechanism for everolimus32,33 and a tardive induc-
tion of apoptosis for nutlin-317,18,41. Interestingly, the co-treatment
induced a slight but significant induction of apoptosis, suggesting
that everolimus could accelerate the induction of apoptosis elicited
by nutlin-3 in prolonged treatment17,18. The different reactivation
kinetics of p53 function and induction of apoptosis elicited by the
two MDM2 inhibitors could be attributed to the more rapid accu-
mulation of p53 protein levels caused by ISA27 with respect to
nutlin-318. With regard to everolimus and FC85, it is important to
mention the intricacy of the AKT/mTOR pathway. mTOR protein
kinase interacts with multiple proteins via its two distinct multipro-
tein complexes, mTORC1 andmTORC243,44, which have been shown
to have distinct signalling in GBM45. Rapamycin and rapalogs,
including everolimus, suppress mTOR activity via an allosteric
mechanism and have been found to be incomplete inhibitors of
mTORC146,47. On this basis, and considering the lack of information
on the detailed mechanism of AKT/mTOR inhibition elicited by
www.nature.com/scientificreports
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Figure 7 | Effect of FC85 and/or ISA27 on sphere-derived cell morphology. GSCs were treated for seven or fourteen days with complete NSC medium
containing DMSO (control), or 500 nM FC85, or 2.5 mM ISA27, alone or in combination. (a) Representative cell micrographs after seven and fourteen
days of treatment are shown. The area of the culture plates occupied by the spheres (b) and the length of cellular processes (c) were scored after seven and
fourteen days of treatment. The counts represent themean values6 SEMof two independent experiments. The significance of differences was determined
with a one-way ANOVA with Bonferroni post-test: * p,0.05, *** p,0.001 vs. control; # p,0.05 vs. FC85 alone; 1 p,0.05 vs. ISA27 alone.
www.nature.com/scientificreports
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FC85, further investigations are needed to obtain insight into the
signalling pathways that are the basis of such differences.
We next characterized our compounds, alone or in combination,
inGSCs isolated fromU87MGcells. First, we demonstrated that both
FC85 and ISA27 induced a time- and concentration-dependent
inhibition of GSC proliferation and triggered apoptosis. In addition,
in GSCs, the combined therapy produced synergisticc effects, accel-
erating the induction of apoptosis and enhancing the inhibition of
GSC viability. Such synergistic interactions were shown also using
the reference compounds nutlin-3 and everolimus, thus confirming
that a combined therapy with an inhibitor of MDM2/p53 complex
and an inhibitor of the AKT/mTOR pathway is useful in anti-
proliferative strategy in GSCs.
To investigate the mechanism underlying these effects, the mor-
phology and stemness/differentiation of GSCs upon treatment with
the compounds were evaluated. Morphological and RT-PCR ana-
lyses demonstrated that FC85 and ISA27 alone significantly
decreased the stemness of GBM-derived cells, and promoted their
differentiation toward a neuronal-glial phenotype. Globally, these
effects elicited by FC85 and ISA27 are in line with the differenti-
ating/pro-apoptotic properties previously reported for AKT/mTOR
inhibitors in GSCs36,48, as well as with the abilities of p53 to induce
differentiation and to suppress self-renewal in human embryonic stem
cells49 and in breast CSCs50, respectively.
When cells were concomitantly treated with the two drugs, a sig-
nificant decrease in the stemness markers was evidenced, together
with amarked increase in neuronal and glial markers, demonstrating
that combining ISA27 and FC85 not only induced apoptosis of GSCs
but also induced the differentiation of these cells.
Then, the signalling pathways most likely implicated in the afore-
mentioned effects were investigated. It has been demonstrated that
the AKT/mTOR signaling pathway is critical for the maintenance of
the properties of gliomaCSCs36,48; on the other hand, in the same cells
the MEK-ERK signalling is required for MDM2 expression, which
prevents p53 activation and subsequent suppression of O(6)-methyl-
guanine DNA methyltransferase expression, thus contributing to
TMZ resistance51. In this study, we showed that FC85 and ISA27
alone inhibited AKT and ERK1/2 phosphorylation up to 30 or
60 min, respectively. Challenging cells with both compounds
prolonged such inhibitions up to 120 min, with significant higher
percentages of inhibition with respect to single agent-treated cells.
These results are in line with the additive/synergic effect on GSC
differentiation elicited by the co-treatment FC851ISA27, and
support the previous demonstrations that the dual inhibition of
PI3K/AKT/mTOR and MEK/ERK signalling induced the differenti-
ation of and inhibited the tumourigenic potential of GSCs38.
Globally, our findings suggest that FC85 actively enhances down-
stream p53 signalling and that a combination strategy aimed at
inhibiting PI3K/AKT/mTOR signalling and activating p53 signalling
is potentially effective in GBM and in its CSC subpopulation, where
TP53 mutations are rare, and the downstream p53 signalling is
intact. The promising anti-tumour effects, confirmed by the com-
bined use of everolimus and nutlin-3, sustain the strength of the
present pharmacological approach, and encourage the extension
of preclinical investigations that, above all, focus on molecular
mechanisms at the basis of such cellular responses.
Methods
Chemical synthesis.Melting points were determined on a Kofler apparatus and are
uncorrected. Chemical shift (d) is reported as part per million downfield from
tetramethylsilane and referenced from solvent references. 1H NMR and 13C NMR
spectra of all compounds were obtained with a Varian Gemini 200 spectrometer
(Labexchange, Burladingen, Germany) operating at 200 MHz, in a,2% solution of
DMSO-d6. The .95% purity of tested compounds was confirmed by combustion
analysis.
Analytical TLC was performed on Merck 0.2-mm precoated silica gel aluminium
(60 F254) sheets t hat were visualized under a UV lamp. Evaporation was performed
in vacuo (rotating evaporator). Sodium sulfate was used as the drying agent.
Commercially available chemicals were purchased from Sigma-Aldrich. The
5-amino-1,3-dihydro-2H-indol-2-one (1) was prepared according to reported
procedures20.
4-methyl-N-(2-oxoindolin-5-yl)benzenesulfonamide (2). To a stirred solution of
5-amino-2-oxindole 1 (148 mg, 1 mmol) in water (10 mL was added TsCl
(228.8 mg, 1.2 mmol) at room temperature, and stirring was continued until the
reaction was complete. Then, the solution was evaporated to dryness. The crude
residue was diluted with MeOH, and the solid product was filtered off from the
mixture. The collected solid was washed with diethyl ether and air-dried. (109 mg,
0.36 mmol, 36% yield): mp 210–212uC.1HNMR: d 2.37 (s, 3H,Me); 3.44 (s, 2H, CH2);
6.65 (d, 1H, J 5 8.2 Hz, Ar); 6.84 (d, 1H, J 5 8.2 Hz, Ar); 6.95 (s, 1H, Ar); 7.32 (d, 1H,
J 5 8.1 Hz, Ar); 7.58 (d, 1H, J 5 8.1 Hz, Ar); 9.89 (br s, 1H); 10.30 (br s, 1H) ppm.
13C NMR: d 170.06, 141.81, 137.46, 135.73, 133.61, 128.85, 128.11, 127.25, 121.99,
117.19, 110.54, 36.42, 21.87 ppm. Anal. Calcd. for C15H14N2O3S: C, 59.59; H, 4.67;
N, 9.27. Found: C, 59.38; H, 4.46; N, 9.03.
(3Z)-N-(3-((1H-imidazol-5yl)-methylene)-2-oxoindolin-5-yl)-4-
methylbenzenesulfonamide (FC85). To a solution of 4-methyl-N-(2-oxoindolin-
5-yl)benzenesulfonamide (2) (118 mg, 0.39 mmol) in ethanol (7 mL) was added the
1H-imidazole-5-carboxaldehyde (41.32 mg, 0.43 mmol) and a catalytic amount of
piperidine. The resulting solution was stirred and refluxed for 12 h; then, the solution
was evaporated to dryness. The crude residue was purified by crystallization from
EtOH, affording FC85 as Z-isomer (79 mg, 0.21 mmol, 53% yield): mp 219–217uC.
1H NMR: d 2.31 (s, 3H, Me); 6.70–6.82 (m, 2H, Ar); 7.32 (d, 1H, J 5 8.1 Hz, Ar); 7.40
(s, 1H, Ar); 7.59 (d, 1H, J 5 8.1 Hz, Ar); 7.73 (s, 1H, Ar); 7.77 (s, 1H, Ar); 8.02 (s, 1H,
H-vinyl); 9.94 (br s, 1H); 10.95 (br s, 1H) ppm. 13C NMR: d 168.90, 139.05, 136.74,
135.45, 134.95, 131.88, 131.40, 130.72, 128.46, 127.59, 127.44, 126.68, 121.33, 117.95,
111.01, 110.12, 21.30 ppm. Anal. Calcd. for C19H16N4O3S: C, 59.99; H, 4.24; N, 14.73.
Found: C, 60.12; H, 4.46; N, 14.87.
Figure 8 | Kinetics of FC85 and/or ISA27 inhibition of AKT and ERK1/2
phosphorylation. U87MG-derived CSCs were treated for the indicated
times (0–120 min) with NSC medium containing DMSO (control), or
500 nMFC85, or 2.5 mMISA27, alone or in combination. At the end of the
treatment periods, the levels of AKT (a) and ERK 1/2 (b) phosphorylation
were evaluated using ELISA kits, as described in the Methods section.
The data are expressed as the percentage of phosphorylated AKT or ERK1/
2 relative to those of untreated cells (control), which were set at 100%, and
are the mean values 6 SEM of three independent experiments performed
in triplicate. The significance of differences was performed using one-way
ANOVA with Bonferroni post-test: * p, 0.05, ** p, 0.01, *** p,0.001
vs. control; # p,0.05, ##p, 0.01 vs. FC85 alone; 1 p,0.05, 11 p,0.01,
111 p,0.001 vs. ISA27 alone.
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GBM cell culture and GSC isolation. The U87MG cell line was obtained from the
National Institute for Cancer Research of Genoa (Italy) and cultured as described18.
To isolate GSCs, approximately 2.0 3 106 cells were suspended in 1 mL of a defined
serum-free Neural Stem Cell (NSC) medium34. After 3–4 days of culture, the
neurospheres were collected, suspended in NSCmedium, dissociated into single cells,
and plated for the assays. For the long-term treatment of cells, NSC or complete
medium containing drugs was replaced every two to three days.
Cell proliferation/viability assays of GBM cells andCSCs.The humanU87MG cells
or GSCswere seeded at a density of 33 103 cells/well. After 24 h, the cells were treated
for one to 7 days with fresh growth medium containing different concentrations of
FC85, ISA27, everolimus or nutlin-3. Following the treatment period, cell viability
was determined using the MTS assay according to manufacturer’s instruction. The
absorbance of formazan at 490 nM was measured in a colorimetric assay with an
automated plate reader (Victor Wallac 2, Perkin Elmer).
For wash-out experiments, U87MG cells or GSCs were treated with FC85 and/or
ISA27 for 96 h (U87MG cells) or seven days (GSCs). At the end of treatments,
medium containing drugs was replaced by fresh medium, and cells were allowed to
grow for the indicated days (one or three days in the case ofU87MG, seven or fourteen
days in the case of GSCs). At the end of treatments, cell viability was measured by the
MTS assay. The results were calculated by subtracting themean background from the
values obtained from each evaluation and were expressed as the percentage of the
control (untreated cells). Sigmoid dose-response curve was generated, fromwhich the
IC50 values were derived.
The effects of compound treatment on U87MG cell viability were also evaluated
using the trypan blue exclusion assay. Cells were treated with different concentrations
(100 nM, 1 mM or 10 mM) of FC85. Following the treatment period, cells were
collected and centrifuged at 300 3 g for 5 minutes. The harvested cells were mixed
with an equal volume of 0.4% trypan blue dye, and the blue (dead cells) and white
(living cells) cells in each well were manually counted. The number of live cells for
each condition was reported as the percentage of living cells relative to that in the
control sample.
Isobolar analysis.Agraphical assessment of synergy with regard to growth inhibition
was performed using isobolographic analysis52. In the present study, the dose of ISA27
or nutlin-3 required to give a 50% effect18 was plotted on the abscissa, and the iso-
effective dose of FC85 or everolimus was plotted on the ordinate. The theoretical
additive effect of the two drugs is represented by the straight line connecting the two
points. If the experimentally determined data points and their confidence interval fall
on this line, the drug effects are additive (no interaction). If the points lie below this
line, there is superadditivity (synergy), and if the points lie above this line, there is
subadditivity (antagonism). To determine whether the interaction between the two
drugs was synergistic, additive or antagonistic, the theoretical additive IC50,add was
estimated from the dose-response curves of each drug administered individually. The
interaction index, denoted by c, is an assessment of the degree of synergism or
antagonism. The index is defined by the isobolar relationship as follows53,54:
c 5a/A 1 b/B where A and B are the doses of drug A (alone) and B (alone) that give
the specified effect, and (a,b) are the combination doses that produce the same effect.
p53 stabilization analysis in U87MG cells. The western blot analysis for the
evaluation of p53 protein levels was performed as previously described18. In brief,
U87MG cells were treated with DMSO (control) or with 500 nM FC85 and 2.5 mM
ISA27, alone or in combination. Alternatively, cells were incubated with 50 nM
everolimus and/or 10 mMnutlin-3, alone or in combination. Cells were then lysed for
60 min at 4uC, and equal amount of the cell extracts (40 mg of proteins) were diluted
in Laemmli solution and resolved by SDS-PAGE41.
RNA extraction andReal Time PCR analysis inU87MG cells and inCSCs.U87MG
cells or GSCs were treated with DMSO (control), 500 nMFC85 and/or 2.5 mMISA27
for 6 h or seven days, respectively. In some experiments, U87MG cells were incubated
with 50 nM everolimus and/or 10 mM nutlin-3 for 6 h or 24 h. At the end of
treatment, the cells were collected, and total RNA was extracted using RNeasyHMini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA
synthesis was performed with 500 ng of RNA using the i-Script cDNA synthesis kit
(BioRad, Hercules, USA) following the manufacturer’s instructions. RT-PCR
reactions consisted of 25 mL of FluocycleH II SYBRH (Euroclone, Milan, Italy), 1.5 mL
of both 10 mM forward and reverse primers, 3 mL of cDNA, and 19 mL of H2O. All
reactions were performed for 40 cycles using the following temperature profiles: 98 uC
for 30 seconds (initial denaturation); T uC (see Suppl. Table S5) for 30 seconds
(annealing); and 72uC for 3 seconds (extension)34.
Cell cycle analysis inU87MG cells.Themeasurement of the percentage of cells in the
different cell phases was performed using the MuseTM Cell Analyser, Merck KGaA,
Darmstadt, Germany). Briefly, U87MG cells were treated for 24 h with DMSO or
500 nM FC85 and 2.5 mM ISA27, alone or in combination. Adherent cells were
collected and centrifuged at 300 3 g for 5 minutes. The pellet was washed with PBS
and suspended in 100 ml of PBS; finally, the cells were slowly added to 1 ml of ice cold
70% ethanol and maintained o/n at 220uC. Then, a cell suspension aliquot
(containing at least 2 3 105 cells) was centrifuged at 300 3 g for 5 minutes, washed
once with PBS and suspended in the fluorescent reagent (MuseTM Cell Cycle
reagent)41.
Annexin V and 7-AAD staining in U87MG cells and in GSCs. Dual staining
with Annexin V conjugated to fluorescein-isothiocyanate (FITC) and 7-amino-
actinomysin (7-AAD) was performed using the commercially available kit (Muse
Annexin V and Dead Cell Kit; Merck KGaA, Darmstadt, Germany). U87MG cells or
GSCs were treated with DMSO (control), FC85 and/or ISA27 for 6 h or seven days,
respectively. In some experiments, U87MG cells were incubated with 50 nM
everolimus and/or 10 mM nutlin-3 for 24 h. At the end of the treatment periods, the
percentages of living, apoptotic and dead cells were acquired and analysed byMuseTM
Cell Analyser, as previously described41.
Quantification of the occupied area and the cellular processes of neurospheres.
GSCs were plated in complete growth medium (day 0) and treated for seven or
fourteen days with 500 nM FC85 and/or 2.5 mM ISA27. At the end of the treatment
period, the drug-containing media were replaced with fresh NSC medium, and the
GSCs were allowed to grow for another 7 or 14 days. Images of the neurospheres were
captured at days 0, 7, 14 and 21. Three different wells were analysed for each
condition, and 15 images of each well were captured34,55. The response of the cultures
to the various treatments was quantified by measuring the area occupied by
neurospheres that had formed, using the ImageJ program (version 1.41; Bethesda,
MD, USA). The cellular processes extending from the six to eight differentiating
neurospheres per condition in three independent experiments were evaluated.
ERK and AKT phosphorylation assays. U87MG cells were cultured in 96-well
microplates (5.000 cells/well) and treated for 2 hours with different FC85
concentrations (100 nM, 1 mM and 10 mM). In kinetic experiments, GSCs were
treated for different times with 500 nM FC85 and/or 2.5 mM ISA27. At the end of the
treatment period, the GSCs were centrifuged at 500 3 g for 3 minutes; cells were
washed twice using fresh saline and rapidly fixed with 4% (for adherent U87MG cells)
or 8% (for suspension GSCs) formaldehyde to preserve the activation of specific
protein modification. The levels of total and phosphorylated AKT and ERK1/2 were
determined using specific primary antibodies. The subsequent incubation with a
secondary HRP-conjugated antibody and the developing solution allowed for the
colorimetric quantification of the levels of total and phosphorylated proteins. The
relative number of cells in eachwell was then determined using the crystal violet assay.
The results were calculated by subtracting themean background value from the values
obtained under each test condition: values were normalized to the number of cells in
each well and are expressed as the percentages of the control (untreated cells) values.
Statistical analyses. The nonlinear multipurpose curve-fitting program Graph-Pad
Prism (GraphPad Software Inc., San Diego, CA) was used for data analysis and
graphic presentations. All data are presented as the mean 6 SEM. Statistical analysis
was performed by one-way analysis of variance (ANOVA) with Bonferroni’s
corrected t-test for post-hoc pair-wise comparisons. P,0.05 was considered
statistically significant.
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